PMID- 38360676
OWN - NLM
STAT- MEDLINE
DCOM- 20240219
LR  - 20240223
IS  - 1746-1596 (Electronic)
IS  - 1746-1596 (Linking)
VI  - 19
IP  - 1
DP  - 2024 Feb 15
TI  - Clinical application of the HM-1000 image processing for HER2 fluorescence in 
      situ hybridization signal quantification in breast cancer.
PG  - 32
LID - 10.1186/s13000-024-01455-8 [doi]
LID - 32
AB  - BACKGROUND: Accurate quantification of human epidermal growth factor receptor 2 
      (HER2) gene amplification is important for predicting treatment response and 
      prognosis in patients with breast cancer. Fluorescence in situ hybridization 
      (FISH) is the gold standard for the diagnosis of HER2 status, particularly in 
      cases with equivocal status on immunohistochemistry (IHC) staining, but has some 
      limitations of non-classical amplifications and such cases are diagnosed basing 
      on additional IHC and FISH. This study investigated the clinical utility of a 
      novel super-resolution fluorescence microscopy technique for the better FISH 
      signal visualization and HER2 FISH classification. METHODS: Fourteen breast 
      cancer tissue samples were retrospectively collected between September 2018 and 
      February 2022, and FISH HER2 signal quantification was evaluated by determining 
      the HER2/chromosome 17 centromere (CEP17) ratio and the number of HER2 signals 
      per nucleus in super- versus conventional-resolution images. RESULTS: 
      Super-resolution images maintained the same overall HER2 diagnosis from routine, 
      but HER2 FISH amplification changed negative to monosomy in two cases. Two 
      Letrozole non-response relapses coincided to monosomy samples. The median number 
      of HER2 signals per nucleus was 7.5 in super-resolution images and 4.0 in 
      conventional-resolution images in HER2-positive samples and 2.8 and 2.1 signals 
      per nucleus, respectively, in HER2-negative samples. CONCLUSIONS: 
      Super-resolution images improved signal visualization, including a significant 
      difference in the number of countable HER2 and CEP17 signals in a single nucleus 
      compared with conventional-resolution images. Increased accuracy of signal 
      quantification by super-resolution microscopy may provide clinicians with more 
      detailed information regarding HER2 FISH status that allows to better FISH 
      classification such as HER2-low samples.
CI  - (c) 2024. The Author(s).
FAU - Peg, Vicente
AU  - Peg V
AD  - Pathology Department, Vall d'Hebron University Hospital, Passeo Vall d'Hebron, 
      119-129, 08035, Barcelona, Spain. vicente.peg@vallhebron.cat.
AD  - Autonomous University of Barcelona, Barcelona, Spain. vicente.peg@vallhebron.cat.
AD  - Spanish Biomedical Research Centre in Cancer (CIBERONC), Madrid, Spain. 
      vicente.peg@vallhebron.cat.
FAU - Moline, Teresa
AU  - Moline T
AD  - Pathology Department, Vall d'Hebron University Hospital, Passeo Vall d'Hebron, 
      119-129, 08035, Barcelona, Spain.
FAU - Roig, Miquel
AU  - Roig M
AD  - Pathology Department, Vall d'Hebron University Hospital, Passeo Vall d'Hebron, 
      119-129, 08035, Barcelona, Spain.
FAU - Saruta, Yuko
AU  - Saruta Y
AD  - Sysmex R&D Center Europe GmbH, Hamburg, Germany.
FAU - Cajal, Santiago Ramon Y
AU  - Cajal SRY
AD  - Pathology Department, Vall d'Hebron University Hospital, Passeo Vall d'Hebron, 
      119-129, 08035, Barcelona, Spain.
AD  - Autonomous University of Barcelona, Barcelona, Spain.
AD  - Spanish Biomedical Research Centre in Cancer (CIBERONC), Madrid, Spain.
LA  - eng
PT  - Journal Article
DEP - 20240215
PL  - England
TA  - Diagn Pathol
JT  - Diagnostic pathology
JID - 101251558
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Breast Neoplasms/diagnosis
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Retrospective Studies
MH  - Neoplasm Recurrence, Local/genetics
MH  - Receptor, ErbB-2/genetics/metabolism
MH  - Monosomy
MH  - Gene Amplification
PMC - PMC10868098
OTO - NOTNLM
OT  - Breast cancer
OT  - Fluorescence in situ hybridization
OT  - HER2 expression
OT  - Super-resolution microscopy
COIS- V.P. has received fees as consultant, participated in advisory boards and 
      received travel grants from Sysmex, Roche, Merck Sharp & Dohme, AstraZeneca, 
      Bayer, Exact Sciences and Daiichi Sankyo. Y.S. is an employee of Sysmex R&D 
      Center Europe GmbH.
EDAT- 2024/02/16 00:42
MHDA- 2024/02/19 06:43
PMCR- 2024/02/15
CRDT- 2024/02/15 23:39
PHST- 2023/10/10 00:00 [received]
PHST- 2024/01/28 00:00 [accepted]
PHST- 2024/02/19 06:43 [medline]
PHST- 2024/02/16 00:42 [pubmed]
PHST- 2024/02/15 23:39 [entrez]
PHST- 2024/02/15 00:00 [pmc-release]
AID - 10.1186/s13000-024-01455-8 [pii]
AID - 1455 [pii]
AID - 10.1186/s13000-024-01455-8 [doi]
PST - epublish
SO  - Diagn Pathol. 2024 Feb 15;19(1):32. doi: 10.1186/s13000-024-01455-8.